Tier 4 — mechanistic

Homocystinuria diagnosis and management: it is not all classical

Adam Gerrard, Charlotte Dawson
Journal of clinical pathology 2022 :jclinpath-2021-208029

Bibliography

PubMed
PMID 36123115
DOI
10.1136/jcp-2021-208029
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
Reported disclosure: Competing interests: None declared.

Study snapshot

DesignClinical narrative review
ModelEvidence synthesis; mixed research models
SampleInherited homocysteine-metabolism disorders
InterventionDiagnostic differentiation and diagnosis-specific treatment
DurationClinical literature review
EndpointsDiagnosis; Methionine patterns; Treatment selection

What the study showed, in plain terms

Published in 2022, this source examined prescription betaine and inherited metabolic disorders. Its evidence base was Inherited homocysteine-metabolism disorders. It evaluated Diagnostic differentiation and diagnosis-specific treatment across Clinical literature review.

Distinguishes CBS deficiency from remethylation disorders and explains why betaine, diet and B12 have different roles across diagnoses.

Not a randomized study. Severe inherited MTHFR deficiency and common MTHFR variants should not be conflated.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • Distinguishes CBS deficiency from remethylation disorders and explains why betaine, diet and B12 have different roles across diagnoses.
  • The recorded outcome domains were Diagnosis; Methionine patterns; Treatment selection.

What this study can and cannot tell us

  • Not a randomized study. Severe inherited MTHFR deficiency and common MTHFR variants should not be conflated.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders
Giorgia Olivieri et al. · Journal of inherited metabolic disease · 2026
Tier 2
Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency
Andrew A M Morris et al. · Journal of inherited metabolic disease · 2017
Tier 4
Postauthorization safety study of betaine anhydrous
Ulrike Mütze et al. · Journal of inherited metabolic disease · 2022
Tier 4
Cystathionine beta synthase deficiency and brain edema associated with methionine excess under betaine supplementation: Four new cases and a review of the evidence
Bernd C Schwahn et al. · JIMD reports · 2020
Tier 2
Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial
Apolline Imbard et al. · Orphanet journal of rare diseases · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology